Gonadorelin vs Kisspeptin.

Gonadorelin is a synthetic decapeptide identical in sequence to endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic hormone that governs the reproductive hypothalamic-pituitary-gonadal axis. It is made as gonadorelin hydrochloride or acetate and has an extremely short circulating half-life of roughly 2 to 10 minutes. Historically it was used in humans both as a diagnostic agent (the GnRH stimulation test, marketed as Factrel) and, in pulsatile-pump form, to treat infertility from hypothalamic causes. Today it is also widely encountered as a compounded product, often paired with testosterone therapy.

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene and cleaved from a 145-amino-acid precursor into fragments named for their length (kisspeptin-54, -14, -13, and -10), all sharing a common C-terminal decapeptide that confers biological activity. Originally identified as the product of a metastasis-suppressor gene (and so called "metastin"), it is now recognized chiefly as the master upstream regulator of the reproductive neuroendocrine axis. It is an endogenous human peptide, not a designer or synthetic-only compound, and acts on a specific G-protein-coupled receptor.

Gonadorelin binds GnRH receptors on pituitary gonadotrope cells, triggering release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Because the natural hormone is secreted in pulses, the pattern of delivery is decisive: brief, intermittent (pulsatile) exposure sustains LH and FSH secretion, whereas continuous exposure desensitizes and down-regulates the receptor, paradoxically suppressing gonadotropins. This pulsatile-versus-continuous distinction is why the same target can be used either to stimulate the axis (pulsatile pumps) or, via long-acting GnRH agonists, to shut it down in prostate cancer and endometriosis. Downstream, LH and FSH drive gonadal production of testosterone or estrogen and support sperm and egg development.

Kisspeptin signals through the receptor KISS1R (formerly GPR54), a Gq/11-coupled GPCR expressed densely on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. Binding triggers phospholipase-C signaling that depolarizes GnRH neurons and stimulates pulsatile GnRH release into the hypophyseal portal system, which in turn drives pituitary secretion of luteinizing hormone (LH) and, more modestly, follicle-stimulating hormone (FSH). Kisspeptin neurons in the arcuate nucleus (co-expressing neurokinin B and dynorphin, the "KNDy" neurons) are thought to constitute the GnRH pulse generator and to relay sex-steroid feedback, while a population in the anteroventral periventricular region mediates the estrogen-driven LH surge. Beyond the hypothalamic-pituitary-gonadal (HPG) axis, KISS1R is expressed in limbic and other brain regions, providing a plausible substrate for effects on sexual and emotional processing.

Pulsatile GnRH therapy has decades of clinical use for inducing ovulation in women with hypothalamic amenorrhea and for restoring fertility in men with congenital hypogonadotropic hypogonadism, and its physiology is well characterized in the endocrine literature. Reviews such as the 2019 Endocrine Reviews synthesis on congenital hypogonadotropic hypogonadism, and reports on pulsatile GnRH in hypothalamic amenorrhea, document reproducible gonadotropin and fertility responses. Most of that literature consists of specialist case series, cohort studies and expert reviews accumulated over decades rather than large modern randomised trials, and it depends on pump-delivered pulsatile administration in patients whose defect is hypothalamic and whose pituitary is intact. As a diagnostic (GnRH stimulation) agent, its ability to provoke measurable LH and FSH release is well established. Evidence for the newer trend of pairing low-dose gonadorelin with testosterone replacement to preserve testicular function is far thinner and largely extrapolated rather than proven in dedicated trials. In short, the strongest evidence supports the classic fertility and diagnostic uses, while other uses are less well supported. Two comparisons make the evidence gap concrete. First, long-acting GnRH agonists and GnRH antagonists, which act at the same receptor to suppress rather than stimulate the axis, were approved on the basis of registrational randomised trials in prostate cancer, endometriosis and assisted reproduction, so the suppressive side of GnRH pharmacology is far better documented than stimulatory gonadorelin use. Second, for maintaining testicular function during androgen therapy, HCG has approved labelling and a substantial published clinical record because it stimulates the LH receptor directly, whereas gonadorelin depends on an intact pituitary and on delivery that mimics natural pulses. Randomised head-to-head comparisons of gonadorelin against HCG for that purpose, and controlled outcome data on sperm parameters or fertility, are not available.

The strongest human evidence is genetic and physiological rather than therapeutic. In 2003 two groups (de Roux et al., PNAS; Seminara et al., NEJM) independently showed that loss-of-function mutations in GPR54/KISS1R cause normosmic idiopathic hypogonadotropic hypogonadism and absent puberty, firmly establishing the pathway's necessity for human reproduction; activating mutations conversely associate with precocious puberty. Controlled human administration studies, largely from the Dhillo/Abbara group at Imperial College London, have repeatedly shown that exogenous kisspeptin acutely raises LH (and to a lesser extent FSH) and that responsiveness varies across the menstrual cycle and with estradiol status (e.g., J Clin Endocrinol Metab 2012 and 2017). Functional-MRI studies in healthy men reported that kisspeptin modulates limbic brain activity to sexual and emotional stimuli (Comninos et al., J Clin Invest 2017; JCI Insight 2018 and 2020). However, kisspeptin remains investigational: it has been explored as a diagnostic and ovulation-triggering tool in fertility settings and studied in hypothalamic amenorrhea, but there are no large phase-3 efficacy trials and no approved kisspeptin drug, so claims of broad libido, fertility, or wellness benefit outrun the existing human data.

In pulsatile fertility use gonadorelin is generally well tolerated; reported effects include injection-site reactions and, with pump therapy, a risk of ovarian hyperstimulation and multiple pregnancy that requires monitoring. Rare hypersensitivity and anaphylaxis-type reactions have been described. Supervised use therefore involves serial hormone measurement and, in ovulation induction, ultrasound follicle tracking, since the point of the therapy is to drive an endocrine axis whose output can overshoot. Because it works through the body's own hormonal axis, its effects depend heavily on the dose pattern and on individual physiology, and the pulsatile versus continuous distinction is a safety issue as well as an efficacy one: non-pulsatile exposure can desensitise pituitary receptors and suppress the very gonadotropins the treatment aims to raise. Supply is a further consideration. The FDA-approved human gonadorelin products were discontinued, so present-day human material comes from compounding pharmacies or, in the grey market, from research-chemical vendors. Compounded preparations are not subject to the batch-level approval, stability testing and labelling standards applied to approved drugs, and research-grade vials carry no assurance of identity, potency, purity or sterility at all. That matters for a peptide with a very short half-life, where the delivered pattern and actual content determine whether the effect is stimulatory, negligible or suppressive. This is educational information only and not a dosing or treatment guide; hormonal therapies should be overseen by a qualified clinician.

In the controlled research settings published to date, single and short-term kisspeptin administration has generally been reported as well tolerated, with its central, on-mechanism effect being stimulation of the reproductive axis. Important unknowns dominate the picture: there are no long-term human safety data, repeated or continuous dosing can desensitize KISS1R signaling (a documented pharmacologic phenomenon), and effects necessarily depend on sex, sex-steroid milieu, and reproductive status. Because the pathway governs the HPG axis, off-label use carries theoretical risks to hormonal balance, ovulation timing, and fertility that have not been characterized outside monitored trials, and material sold as "research" kisspeptin has no assurance of identity, purity, or sterility. It is not an approved medicine for any consumer indication.

Gonadorelin was FDA-approved for humans in the 1980s, including Factrel (gonadorelin hydrochloride) for the GnRH stimulation test and Lutrepulse for pulsatile ovulation induction, but these human products have since been discontinued in the US market. DailyMed currently lists gonadorelin only in approved veterinary products (for example Factrel, Cystorelin, Fertagyl), and present-day human access is largely through compounding pharmacies. It remains a recognized drug substance rather than a dietary supplement.

Kisspeptin is investigational/research-use-only: as of 2026 there is no FDA-approved kisspeptin product, and human use has occurred under research protocols (e.g., as an experimental fertility and diagnostic agent), not as an approved drug. It is not a controlled substance and is not specifically a WADA-prohibited compound, but its regulatory status as an unapproved peptide means it is not legally marketed for human treatment.